Valeant pays $65m for US rights to Eisai's Targretin as competition for the CTCL drug mounts
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals paid $65 million up front to add the Eisai cutaneous T-cell lymphoma (CTCL) drug Targretin (bexarotene) to its growing dermatology portfolio just as competition to treat the orphan indication is set to increase.